Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and Thymalfasin with Chemoradiotherapy in pMMR/MSS LARC
NCT06056804Phase 2Active, not recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- Jan 2024
- Primary completion
- Dec 2024
- Modality
- Peptides, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, thymosin alpha 1 in rectal cancer, sponsored by Beijing Friendship Hospital. Started Jan 2024; status: active, not recruiting.
02
Drugs
tislelizumabthymosin alpha 1
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06056804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06056804.